With effect from 2015 all the annual financial statements of the Leriva companies are prepared in accordance with the Greek Accounting Standards (Law 4308/2014) which incorporates the provisions of European Directive 2013/34/EU on annual financial statements. For prior years the annual financial statements of the Group’s companies were prepared under Greek GAAP ("GAAP") and the accounting provisions of Law 2190/1920.
Consolidated sales for the fiscal year ended December 31, 2024, amounted to €22,432,985, representing a 6.5% increase compared to €21,064,598 in 2023. While sales growth was solid, a slight contraction in the gross profit margin, together with higher operating expenses and increased financing costs, weighed on bottom-line performance. Consolidated net income for 2024 totaled €1,058,951, or 4.7% of sales, reflecting a 15.2% decrease from €1,248,826, or 5.9% of sales, recorded in the prior year.
The annual financial statements of each of the Leriva legal entities can be accessed by clicking on the links below..
Leriva Holdings SA
Leriva SA
Leriva Diagnostics SA
Leriva Pharma SA (formerly Leriva Imaging SA)
